Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins

Saved in:

Bibliographic Details
Published in	Blood cancer journal (New York) Vol. 11; no. 6; pp. 108 - 6
Main Authors	Blaeschke, Franziska, Stenger, Dana, Apfelbeck, Antonia, Cadilha, Bruno L., Benmebarek, Mohamed-Reda, Mahdawi, Jasmin, Ortner, Eva, Lepenies, Mareike, Habjan, Nicola, Rataj, Felicitas, Willier, Semjon, Kaeuferle, Theresa, Majzner, Robbie G., Busch, Dirk H., Kobold, Sebastian, Feuchtinger, Tobias
Format	Journal Article
Language	English
Published	London Nature Publishing Group UK 04.06.2021 Springer Nature B.V Nature Publishing Group
Subjects	13/31 13/44 631/250/251 631/67/1990/283/2125 692/699/1541/1990/283/2125 Antigens, CD19 - immunology Biomedical and Life Sciences Biomedicine Cancer Research CD28 Antigens - therapeutic use Cell Line, Tumor Correspondence Hematology Humans Immunotherapy, Adoptive Oncology Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - immunology Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - therapy Programmed Cell Death 1 Receptor - therapeutic use Receptors, IgE - immunology Recombinant Fusion Proteins - pharmacology
Online Access	Get full text
ISSN	2044-5385 2044-5385
DOI	10.1038/s41408-021-00499-z

More Information
Bibliography:	SourceType-Scholarly Journals-1 ObjectType-Correspondence-1 content type line 14 ObjectType-Article-2 content type line 23
ISSN:	2044-5385 2044-5385
DOI:	10.1038/s41408-021-00499-z